Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Bruix, Jordi *, Qin, Shukui, Merle, Philippe, Granito, Alessandro, Huang, Yi-Hsiang, Bodoky, György, Pracht, Marc, Yokosuka, Osamu, Rosmorduc, Olivier, Breder, Valeriy, Gerolami, René, Masi, Gianluca, Ross, Paul J, Song, Tianqiang, Bronowicki, Jean-Pierre, Ollivier-Hourmand, Isabelle, Kudo, Masatoshi, Cheng, Ann-Lii, Llovet, Josep M, Finn, Richard S, LeBerre, Marie-Aude, Baumhauer, Annette, Meinhardt, Gerold, Han, Guohong
Zdroj: In The Lancet 7-13 January 2017 389(10064):56-66
Databáze: ScienceDirect